Discrepancies between publication, protocol and registration
May 12, 2021 Ioana A. Cristea, Florian Naudet, Clara Miguel 1 citation preprint
A letter to the editor critiques the design and interpretation of a trial comparing psilocybin to escitalopram for depression, arguing that the study's conclusions may be overstated due to methodological issues such as lack of adequate blinding and potential expectancy effects. The author suggests that the reported benefits of psilocybin could be influenced by these factors, and calls for more rigorous research to confirm its efficacy relative to established treatments.